Bodea Ioan Cătălin, Ciocan Andra, Zaharie Florin Vasile, Bodea Raluca, Graur Florin, Ursu Ștefan, Ciocan Răzvan Alexandru, Al Hajjar Nadim
Department of Surgery, "Iuliu Hațieganu" University of Medicine and Pharmacy, Croitorilor Street, No. 19-21, 400162 Cluj-Napoca, Romania.
"Octavian Fodor" Regional Institute of Gastroenterology and Hepatology, Croitorilor Street, No. 19-21, 400162 Cluj-Napoca, Romania.
J Pers Med. 2024 Apr 27;14(5):463. doi: 10.3390/jpm14050463.
Pancreatic cancer is one of the most aggressive, heterogeneous, and fatal types of human cancer; therefore, more effective therapeutic drugs are urgently needed. Human epidermal growth factor receptor 2 (HER2) overexpression and amplification have been identified as a cornerstone in this pathology. The aim of this review is to identify HER2 membrane overexpression in relation to pancreatic cancer pathways that can be used in order to develop a targeted therapy. After searching the keywords, 174 articles were found during a time span of 10 years, between 2013 and 2023, but only twelve scientific papers were qualified for this investigation. The new era of biomolecular research found a significant relationship between HER2 overexpression and pancreatic cancer cells in 25-30% of cases. The variables are dependent on tumor-derived cells, with differences in receptor overexpression between PDAC (pancreatic ductal adenocarcinoma), BTC (biliary tract cancer), ampullary carcinoma, and PNETs (pancreatic neuroendocrine tumors). HER2 overexpression is frequently encountered in human pancreatic carcinoma cell lines, and the ERBB family is one of the targets in the near future of therapy, with good results in phase I, II, and III studies evaluating downregulation and tumor downstaging, respectively.
胰腺癌是人类癌症中最具侵袭性、异质性和致命性的类型之一；因此，迫切需要更有效的治疗药物。人类表皮生长因子受体2（HER2）的过表达和扩增已被确定为这一病理过程的基石。本综述的目的是确定与胰腺癌相关途径中HER2膜过表达情况，以便开发靶向治疗。在搜索关键词后，在2013年至2023年的10年时间跨度内共找到174篇文章，但只有12篇科学论文符合本次研究要求。生物分子研究的新时代发现，在25%-30%的病例中，HER2过表达与胰腺癌细胞之间存在显著关联。这些变量取决于肿瘤来源细胞，在胰腺导管腺癌（PDAC）、胆管癌（BTC）、壶腹癌和胰腺神经内分泌肿瘤（PNET）之间，受体过表达存在差异。HER2过表达在人类胰腺癌细胞系中经常出现，ERBB家族是未来治疗的靶点之一，在评估下调和肿瘤降期的I期、II期和III期研究中分别取得了良好结果。
